The company plans to use the proceeds to fund clinical studies on the use of neuromodulation as a treatment for autoimmune diseases. The studies will begin with a focus on inflammatory bowel disease, according to a Nov. 1 Boomerang Medical news release.
Arboretum Ventures and Hatteras Venture Partners led the funding round. The company has now raised a total of $18 million.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
